ERNA

DEF 14C - Ernexa Therapeutics Inc. (0000748592) (Filer)

PRE 14C - Ernexa Therapeutics Inc. (0000748592) (Filer)

Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026 with first-in-human study planned for Q4 2026 for the treatment of platinum-resistant ovarian cancer Multiple regulatory and clinical milestones expected to drive significant value creation over the next 12-18 months CAMBRIDGE, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today provided a business update highlighting the Company's accelerating t

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-3/A - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

10-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that Sanjeev Luther, President & CEO of Ernexa, will participate in the Virtual Investor Closing Bell Series on Wednesday, February 25, 2026, at 4:00 PM ET. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, will provide a corporate overview and business outlook. In addition to the moderated discussion

4 - Ernexa Therapeutics Inc. (0000748592) (Issuer)

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

424B5 - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (NASDAQ:ERNA) ("Ernexa" or the "Company"), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 21,000,000 shares of common stock, at a combined public offering price of $0.50 per share (or per common stock equivalent in lieu thereof) and accompanying warrant. The warrants will have an exercise price of $0.68 per share, will be exercisable upon issuance, and will e

EFFECT - Ernexa Therapeutics Inc. (0000748592) (Filer)

CERT - Ernexa Therapeutics Inc. (0000748592) (Filer)

8-A12B - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-1/A - Ernexa Therapeutics Inc. (0000748592) (Filer)

S-1/A - Ernexa Therapeutics Inc. (0000748592) (Filer)

Access the "What This Means" segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment discussing the Company's recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa's development strategy for its lead cell therapy,

S-1 - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program (JEAP), a highly competitive initiative launched by the Japan External Trade Organization (JETRO). JEAP drew approximately 70 regenerative medicine companies from 25 countries, underscoring the competitiveness of the selection process. Ernexa was chosen for its differentiated cell therapy platform and its potential to contribute meaningfully to Japan's globally

Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH) trial for the treatment of ovarian cancer in the second half of 2026 CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the successful completion of its recent Pre-Investigational New Drug Application (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA). Feedback from the FDA provided strong regulatory alignment on Ernexa's development approach and set

8-K - Ernexa Therapeutics Inc. (0000748592) (Filer)

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead cell therapy candidate, ERNA-101, at the American Society of Hematology (ASH) Annual Meeting. The data demonstrated that its proprietary cell therapy platform can rapidly and durably reprogram immunosuppressive tumor microenvironments (TMEs) into immune-active, pro-inflammatory states to combat cancer. The platform engineers induced pluripotent stem cells (iPSCs) and transforms them into induced mesenchymal stem cells (iMS

CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that data from its novel cell therapy platform will be shared in an oral presentation at the 67th ASH Annual Meeting, being held December 6-9, 2025 in Orlando, FL. "Being selected to give an oral presentation at ASH is a tremendous honor and a major milestone," said Sanjeev Luther, President & CEO of Ernexa Therapeutics. "It's a recognition of the potential of our iMSC platform to transform the tumor microenvironment and drive a targeted immune response. We're proud to share